Wed, January 22, 2025
Tue, January 21, 2025
Mon, January 20, 2025
Sun, January 19, 2025
Sat, January 18, 2025
Fri, January 17, 2025

Jim Cramer on Eli Lilly and Company (LLY)'s Q4 2024 Performance: 'Aren't As Strong As Wall Street Was Hoping'


//stocks-investing.news-articles.net/content/202 .. -aren-t-as-strong-as-wall-street-was-hoping.html
Published in Stocks and Investing on Sunday, January 19th 2025 at 6:41 GMT by MSN   Print publication without navigation

  • We recently compiled a list of the 9 Stocks on Jim Cramer's Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer's radar.

Jim Cramer discussed Eli Lilly and Company's (LLY) Q4 2024 performance on CNBC, noting that the company's results did not meet Wall Street's expectations. Despite Eli Lilly reporting a significant year-over-year revenue increase, the growth was primarily driven by Mounjaro, their diabetes drug, while other segments underperformed. Cramer highlighted that while the company's earnings per share were above consensus estimates, the overall revenue fell short, leading to a mixed reaction in the stock market. He also mentioned concerns about the sustainability of Mounjaro's sales growth and the competitive landscape in the pharmaceutical industry, suggesting that investors should temper their expectations for Eli Lilly's stock in the near term.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/jim-cramer-on-eli-lilly-and-company-lly-s-q4-2024-performance-aren-t-as-strong-as-wall-street-was-hoping/ar-AA1xsqku ]

Publication Contributing Sources